UZEDY® continues strong growth; Teva setting the stage for US NDA Submission for Olanzapine LAI in Q4 2025
November 5, 2025
November 5, 2025
FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
October 10, 2025
October 10, 2025
Teva and Medincell’s Risperidone LAI Approved in Canada as LONGAVO®
September 23, 2025
September 23, 2025
New Data Show that UZEDY® Initiation in Hospitalized Patients is Associated with Faster Discharge and an Overall Clinician Preference Compared to Invega Sustenna®
September 22, 2025
September 22, 2025
UZEDY® Approved in South Korea
September 10, 2025
September 10, 2025
UZEDY® Accelerates: 2025 Revenue Outlook Raised to $190–$200M (from ~$160M); Olanzapine LAI on Track for Submission in 2025
July 30, 2025
July 30, 2025
UZEDY® Continues Strong Momentum in 2025; Olanzapine LAI on Track for FDA Filing in H2 2025
May 7, 2025
May 7, 2025
Phase 3 Survey Results Demonstrate Patient and Healthcare Professional Satisfaction with Olanzapine LAI
March 31, 2025
March 31, 2025
FDA Acceptance of Supplemental New Drug Application for UZEDY® as a Treatment for Patients with Bipolar I Disorder
February 25, 2025
February 25, 2025
UZEDY® Surges to $117M in Sales in 2024, First Full Year of Commercialization
